← Back to Search

HPV Vaccine and Screening Strategy for Cervical Cancer

N/A

Recruiting

Led By Jane Montealegre, M D

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Females; Age ≥30 years

Have no history of hysterectomy with removal of the cervix

Must not have

Unable to communicate in English or Spanish

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial found that HPV vaccine and cervical screening can help prevent cervical cancer.

Who is the study for?

This trial is for women aged 30 or older living in RGV who haven't had a Pap test in the last 3.5 years or a Pap/HPV co-test in the past 5.5 years, and have not been diagnosed with cervical cancer or severe cervical dysplasia. Participants must be able to understand English or Spanish, are not pregnant, and do not belong to vulnerable populations.

What is being tested?

The study tests a community-based strategy called PRECEDE-PROCEED aimed at improving access to cervical cancer screening for early detection of potential disease caused by HPV.

What are the potential side effects?

Since this trial focuses on a public health intervention rather than medication, it does not involve typical drug side effects. However, participants may experience discomfort during screening procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman aged 30 or older.

Select...

I have not had a hysterectomy that removed my cervix.

Select...

I have never had cervical cancer or severe abnormal cell changes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot communicate in English or Spanish.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: PRECEDE-PROCEEDExperimental Treatment1 Intervention

To identify predisposing, enabling, and reinforcing factors that could influence women's decision to participate in self-sample HPV testing and diagnostic follow-up.

0 / 4Eligibility criteria met